Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas

PURPOSETumors with neomorphic mutations in IDH1/2 have defective homologous recombination repair, resulting in sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition. The Olaparib Combinatio...